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Abstract 
Background: As an important component of the Hippo pathway, WW domain-containing transcription regulator 1 
(TAZ), is a transcriptional coactivator that is responsible for the progression of various types of cancers. Programmed 
cell death protein 1 (PD-1) receptors in activated T cells and their ligand programming death force 1 (PD-L1) are the 
main checkpoint signals that control T cell activity. Studies have shown high levels of PD-L1 in various cancers and 
that PD-L1/PD-1 signals to evade T-cell immunity. Recent data have demonstrated that TAZ can regulate the char-
acteristics of cancer cells via PD-L1. Cervical cancer is a common gynecological disease worldwide. In this study, we 
attempted to evaluate the effects of TAZ and PD-L1 on cervical cancer.
Methods: Hela cervical cancer cells were transfected with TAZ plasmid or TAZ siRNA or PD-L1 siRNA by using Lipo-
fectamine 2000. The relationship between TAZ and PD-L1 in cervical cancer cells was determined by qRT-PCR and 
western blotting. The functional roles of TAZ were confirmed via CCK-8, Transwell and flow cytometry assays. Western 
blotting was utilized to observe the expression of BCL-2 and Caspase-3. The clinicopathological correlation of TAZ and 
PD-L1 was evaluated via relevant databases.
Result: TAZ is upregulated in cervical cancer and induces the growth and metastasis of cervical cancer cells by 
targeting PD-L1and inhibiting the ratio of apoptotic of cancer cells. High TAZ and PD-L1 expression was observed in 
different stage, grade, histological patterns, and ages of cervical cancer groups compared with normal cervix groups. 
Furthermore, high TAZ expression was positively correlated with the infiltration levels of immune cells and the expres-
sion of PD-L1.
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Introduction
Cervical cancer (CC) is the second most common cancer 
among women in the worldwide and it has a high mor-
tality rate [1]. Although significant achievements have 
been made in CC therapy, its prognosis of it is still poor 
due to the high metastasis and recurrence [2]. Thus, it is 
necessary to find new treatment methods and molecular 
mechanisms for CC.
As an evolutionary preservation pathway, the Hippo 
signaling pathway can control the size of organs and 
regulate cell proliferation, self-renewal, differentiation, 
and survival [3]. Moreover, Hippo signaling can have 
two important roles, tumor-suppressive and oncogenic 
activities, in different tumors [4]. WW domain-contain-
ing transcription regulator 1 (TAZ) is a downstream 
nuclear effector in the Hippo pathway that induces the 
proliferation and inhibits the apoptosis of cancer cells 
[5, 6]. A large number of studies have shown that high 
expression of TAZ can cause Epithelial-mesenchymal 
transition (EMT), inhibit apoptosis of cancer cells, and 
increase the number of cancer stem cells in vitro [7, 8]. 
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on the migration, invasion, and tumorigenesis of cancer 
cells in nude mice [9, 10]. Nevertheless, little research has 
focused on the role of TAZ in the Hippo pathway in CC. 
In previous studies, TAZ levels were observed to increase 
in cervical cancer and its microenvironments [11]. How-
ever, the precise mechanism of this process in CC cells 
remains uncertain.
The PD-1/PD-L1 axis immune checkpoint pathway can 
induce immune evasion of cancer cells and thus inhibit 
the immune response in various solid tumors, includ-
ing CC [12]. Overexpression of PD-L1 has been found in 
human CC [13, 14]. PD-L1 can not only mediate T cell 
suppression but also promote cancer cell growth and 
invasion [15]. Early studies have indicated that the Hippo 
pathway can affect the immune response to cancer and 
the recruitment and activation of immune cells [16, 17]. 
The upstream factors mammalian STE20-like kinase 
1 and 2 (MST1/2) and large tumor suppressor 1 and 2 
(LATS1/2) can inhibit PD-L1 expression, while TAZ and 
YAP induce high expression of PD-L1 in breast and lung 
cancer cell lines [18]. Comparison results indicate that 
TAZ activity can affect PD-L1 expression in cancer cell 
lines and that the TAZ/YAP/TEAD pathway increases 
PD-L1 promoter activity [18]. However, no research has 
demonstrated the correlation of TAZ and PD-L1 in CC 
and their effects on the tumor characteristics of CC.
Therefore, it is important to evaluate the effects of TAZ 
and PD-L1 on CC. We showed that TAZ is upregulated 
and can regulate cell proliferation, invasion, apoptosis, 
and clinical significance through PD-L1 in the CC in our 
study. Additionally, significant correlation between TAZ 
expression and the infiltration levels of immune cells and 
the expression of PD-L1 were observed in this research.
Materials and methods
Cell culture
The cervical cancer cell line HeLa (ACC, USA) was main-
tained in minimal essential medium (MEM) (HyClone™; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
supplemented with 10% fetal bovine serum (FBS) 
(HyClone™) at 37 °C in a humidified atmosphere of 95% 
air and 5%  CO2.
Cell transfection
At 24 h prior to transfection, HeLa cells were plated into 
6-well plates at a density of 5 ×  105 per well and were then 
transfected with 100 pmol of TAZ siRNA or nonspecific 
sequence control (NC) using Lipofectamine 2000 (Inv-
itrogen, USA) according to the manufacturer’s protocol. 
PD-L1 siRNA was transfected in a similar manner. The 
untransfected HeLa cells were also a negative control.
The coding sequence (CDS) of the human TAZ gene 
was amplified from the cDNA of the cervical cancer cell 
line SiHa by polymerase chain reaction (PCR) using the 
following primers:
TAZ-F: CCC AAG CTT ATG CCT CTG CAC GTG AAG 
HindIII.
TAZ-R: CCG GAA TTC TCT CCC AGG CTG GAG GTG 
EcoRI.
A pcDNA3 eukaryotic expression vector (Invitrogen, 
San Diego, CA, USA) was used to establish stably trans-
fect cells overexpressing TAZ. To construct pcDNA3-
TAZ, the full-length human TAZ gene pB4 was 
digested with EcoRI and then inserted into an EcoRI-
cleaved pcDNA3 vector. Cells were transfected with 
pcDNA3 or pcDNA3-TAZ using the lipofection tech-
nique according to the manufacturer’s protocol (Gibco 
BRL, Life Technologies, Rockville, MD, USA).
Quantitative real‑time polymerase chain reaction 
(RT‑qPCR)
Total RNA was extracted using  TRIzol® (Transgene, 
China) from parental and transfected HeLa cells, fol-
lowed by isopropanol precipitation and chloroform 
extraction. cDNA was synthesized using the Reverse 
Transcriptase system (Invitrogen; Thermo Fisher Scien-
tific, Inc.), in accordance with the manufacturer’s pro-
tocol. RT-PCR was performed using an iCycler™ Real 
Time system (Bio-Rad Laboratories, Richmond, CA, 
USA) using the SYBR Premix EX Tag Master mixture 
kit (Takara Bio, Inc.) according to the manufacturer’s 
protocol. The quantification of gene transcription was 
normalized to GAPDH mRNA. The primers used in 
this study were as follows:
TAZ: Primer F 5′ TCA TCA CCG TGT CCA ATC 3′.
Primer R 5′ CTG AAG AAG TGG GAG TGT AG 3′.
GAPDH: Primer F 5′ CAC CCA CTC CTC CAC CTT 
TG 3′.
Primer R 5′ CCA CCA CCC TGT TGC TGT AG 3′.
The samples were amplified in different wells and run 
in triplicate. The relative expression of genes was com-
pared with the  2−ΔΔCt relative quantification method.
CCK‑8 assay
The effects of TAZ on HeLa cell proliferation were 
measured by Cell Counting Kit-8 (CCK-8) (Sigma–
Aldrich, USA). HeLa cells were plated at a density of 
5 ×  103 cells per well in 96-well plates 24 h after trans-
fection. Thereafter, 10 µl CCK solution and 100 µl fresh 
medium were added to each well, and the plates were 
incubated in the dark at 37 °C for 2 h. After incubation, 
the absorbance at 452 nm was measured using a Multi-
skan Go spectrometer (Thermo Fisher, USA).
Page 3 of 14Han et al. Cancer Cell Int          (2021) 21:592  
Transwell invasion assay
A total of 1 ×  105 cells per well in triplicate were plated 
in the upper chamber of a 24-well plate (pore size 8 µm, 
Corning, USA) containing 200  µl of serum-free MEM 
medium. For the invasion assay, the base of the upper 
chambers was coated with extracellular Matrigel (BD 
Biosciences, USA) to serve as a chemoattractant. Cells 
were allowed to invade for 24 h. The Transwell chamber 
was then removed, the culture solution in the Transwell 
chamber was discarded, and the chamber was washed 
twice with calcium-free phosphate-buffered saline 
(PBS). After that, the chamber was fixed in methanol 
solution for 30  min and stained with 0.1% crystal vio-
let for 20 min at room temperature. The chamber was 
washed several times with PBS, and the upper cham-
ber liquid was aspirated. The unmigrated cells in the 
upper layer were gently wiped off using a cotton swab. 
The microporous membrane was removed carefully 
with small tweezers and dried with the bottom side up. 
Next, the membrane was transferred to a glass slide and 
sealed with neutral gum. Images were observed and 
collected by an inverted optical microscope (Keyence, 
Osaka, Japan).
Annexin V/propidium iodide apoptosis assay
Apoptosis assays were performed using a commercially 
available kit, per the manufacturer’s protocol. HeLa 
cells (control), including the negative control (NC) and 
cells carrying TAZ siRNA, PD-L1 siRNA, or the TAZ 
plasmid, or cotransfected with the TAZ plasmid and 
PD-L1 siRNA were plated at 5 ×  105/well in each well 
of 6-well plates in duplicate. After 24 h, the cells were 
harvested by trypsinization and suspended in PBS. The 
cells were subsequently suspended in 500  µl binding 
buffer (BD Biosciences, USA). Later, 5 µl annexin-V flu-
orescein isothiocyanate (FITC) (BD Biosciences, USA) 
and 5  µl propidium iodide (PI) (both purchased from 
BD Biosciences, USA) were added, and the cells were 
incubated for 20  min in the dark. Finally, the samples 
were analyzed using flow cytometric analysis.
Western blotting
Antibodies against Bcl-2, Caspase-3, PD-L1, MMP-2 and 
MMP-9 were purchased from Abcam Group, Inc. The 
Table 1 Antibodies
Primary antibodies Clonality Catalogue number Company Species Dilution Diluent
MMP2 Monoclone 66366-1-Ig Proteintech Mouse 1:1000 Non-fat milk
MMP9 Monoclone ab76003 Abcam Rabbit 1:500 Non-fat milk
Bcl-2 Monoclone ab32124 Abcam Rabbit 1:1000 Non-fat milk
Caspase-3 Monoclone Ab32351 Abcam Rabbit 1:500 Non-fat milk
PD-L1 Monoclone Ab205961 Abcam Rabbit 1:500 Non-fat milk
GAPDH Monoclone 60004-1-Ig Proteintech Mouse 1:500 Non-fat milk
Fig. 1 Expression of TAZ and PD-L1 in CC. A and B The Oncomine 
database showed that the expression of TAZ was higher in the CC 
and CSCC groups than in the normal cervix group. C and D CC and 
CSCC demonstrated increased expression of PD-L1 compared with 
normal groups. *P < 0.05 vs. the control group. CC, cervical cancer. 
CSCC, cervical squamous cell cancer
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information regarding the antibodies is summarized in 
Table  1. The normal and transfected cells were scraped 
on ice, collected by centrifugation (12,000×g, 10  min, 
4  °C) for protein extraction, incubated with freshly pre-
pared RIPA lysis buffer for 15  min, and then quantified 
with a bicinchoninic acid (BCA) kit (Nanjing KeyGen 
Biotech. Co., Ltd.). The protein sample was mixed with 
loading buffer and boiled for 8  min. Subsequently, the 
sample was separated on a 10% SDS–PAGE gel and 
electrotransferred onto PVDF membranes (Merck Mil-
lipore). The membranes were incubated for 1 h at room 
temperature with 5% fat-free milk in Tris-buffered saline 
Fig. 2 Box plots evaluating TAZ and PD-L1 expression among different groups of patients based on clinical parameters using the UALCAN 
database. Analysis is shown for sample types (A and G), metastasis (B and H), cancer stage (C and I), tumor histology (D and J) tumor grade (E and 
K) and age (F and I). *P < 0.05
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containing Tween-20, followed by incubation overnight 
at 4 °C with primary antibodies. Protein bands were cap-
tured by a Li-Cor Odyssey Imaging system (LI-COR Bio-
sciences, USA).
Oncomine database analysis
The expression levels of the TAZ and PD-L1 genes in cer-
vical cancer were identified in the Oncomine database 
(https:// www. oncom ine. org/ resou rce/ login. html). The 
threshold was determined according to the following val-
ues: P value < 0.05.
UALCAN
UALCAN (http:// ualcan. path. uab. edu/) is a web-based 
tool that provides in-depth analyses of transcrip-
tome data from The Cancer Genome Atlas (TCGA) 
and MET500 data. UALCAN was used to investigate 
the expression of TAZ and PD-L1 and the association 
between TAZ and PD-L1 and various clinicopathological 
parameters of lung CC.
Gene expression profiling interactive analysis (GEPIA) 
and R2 database
GEPIA (http:// gepia. cancer- pku. cn/ index. html) is a user-
friendly web portal for gene expression analysis based on 
TCGA and GTEx data. The relationships between hep-
cidin and PD-1, PD-L1 and CTLA-4 were determined 
using Spearman’s correlation coefficient in “correlation 
analysis”. Additionally, to verify the correlation of TAZ 
and PD-L1 in patients with CC, an R2 database was used 
to analyze the relationship of TAZ and PD-L1.
Tumor immune estimation resource (TIMER)
TIMER (https:// cistr ome. shiny apps. io/ timer/), an inter-
active web portal, performs comprehensive analysis on 
the infiltration levels of different immune cells. In the 
present study, TAZ expression in multiple types of can-
cer was evaluated through the “Diff Exp” module. The 
correlation of TAZ and immune cell infiltration in CC 
was analyzed in TIMER. The “Gene” module was used 
to investigate the relationship between TAZ expression 
and immune cell infiltration levels (B cells, CD8 + T cells, 
CD4 + T cells, neutrophils, macrophages, and dendritic 
cells) using the TCGA database.
Statistic analysis
All statistical analyses were completed by using SPSS 
Inc. (Chicago, IL, USA). The Results are presented as 
the mean ± standard deviation (SD) or standard error of 
the mean. Statistical significance was determined using 
ANOVA analysis followed by Tukey’s post hoc test. The 
Spearman rank order correlation was used for the pair-
wise correlation analyses of expression between proteins. 
P < 0.05 was considered to indicate a statistically signifi-
cant value.
Result
TAZ and PD‑L1 are upregulated in CC
To observe the difference of expression of TAZ and 
PD-L1, a comprehensive analysis of hepcidin expression 
profiles was conducted using publicly assessable datasets 
from Oncomine database. The expression of TAZ mRNA 
was found to be increased in the CC group compared 
with the normal group (Fig.  1A and B). We also found 
that PD-L1 expression was higher in CC tissues from 2 
different cohorts (Fig. 1C and D).
Fig. 3 The methylation of TAZ and PD-L1 on CC. A The UALCAN database showed that the level of methylation of TAZ was higher in the CC group 
than in the normal cervix group. B The PD-L1 methylation level was higher in the CC group than in the normal group. *P < 0.05 vs. the control 
group. CC, cervical cancer
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Expression of TAZ and PD‑L1 and clinical parameters of CC 
patients
Considering of the high expression of TAZ and PD-L1, 
we then focused our investigation on CC and explored 
the clinical significance of TAZ and PD-L1 expression 
related to patient survival and disease progression. By 
using the UALCAN online tool, we then investigated 
TAZ and PD-L1 expression among groups of patients 
according to different clinical parameters. The expression 
of TAZ and PD-L1 was increased in Cervical squamous 
cell carcinoma and endocervical adenocarcinoma.
(CESCs) compared with normal controls (Fig. 2A and 
G). According to metastasis status, TAZ and PD-L1 
expression were significantly upregulated in CESC sam-
ples classified as N0 and N1 compared to the correspond-
ing normal controls; however, the expression of TAZ was 
lower in patients classified as N1 than in patients clas-
sified as No (Fig.  2B and H). Regarding tumor stage, a 
significant increase in TAZ expression was observed in 
CESC patients in stages 1, 2, 3, and 4, and a significantly 
increased expression of PD-L1 was observed in CESE 
patients in stages 1, 2, and 3 (Fig.  2C and I). Based on 
tumor histology, TAZ expression was higher in patients 
with squamous, endocervical, and mucinous cell types 
(Fig. 2D). PD-L1 expression was higher in the squamous 
cell type of CESC (Fig.  2J). Upregulation of TAZ and 
PD-L1 expression was observed in the grade 1, 2, and 3 
CESC groups compared to the normal controls (Fig. 2E 
and K). In terms of age, the TAZ level was significantly 
elevated in CESC patients from different age groups (21–
40 years, 41–60 years, 61–80 years) (Fig. 2F). In addition, 
PD-L1 expression was dramatically increased in CESC 
patients aged 21–40 years, 41–60 years, and 61–80 years 
(Fig. 2L). These results suggest that there is a significant 
correlation between the expression of TAZ and PD-L1 
and the clinical parameters of CESC patients.
Methylation of TAZ and PD‑L1 in CC patients
We used the UALCAN database to observe the meth-
ylation levels of TAZ and PD-L1. The methylation lev-
els of the TAZ promoter tended to be higher in normal 
controls than in CESC patients (Fig.  3A). Similarly, 
Fig. 4 Correlation of TAZ expression with immune infiltration level in CC. A TAZ expression is significantly negatively related to tumor purity and 
has significant positive correlations with infiltrating levels of CD4 + T cells in CC, other than CD8 + T cells, B cells, macrophages, neutrophils, and 
dendritic cells. B PD-L1 expression has significant positive correlations with infiltrating levels of CD4 + T cells in CC, CD8 + T cells, macrophages, 
neutrophils, and dendritic cells. C The GEPIA database indicated a positive correlation of TAZ and PD-L1 (CD274) and a negative association 
between TAZ and PD-1 (PDCD1) and CTLA4 in CC. *P < 0.05. CC, cervical cancer
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PD-L1 promoter methylation levels were dramatically 
higher in the normal controls than in the CESC groups 
(Fig.  3B). These results indirectly demonstrated that 
the CESC groups showed higher expression of TAZ 
and PD-L1.
Correlation analysis between TAZ expression 
and infiltrating immune cells
To further assess the effect of TAZ and PD-L1 on the 
tumor microenvironment (TME), we estimated the 
correlation between TAZ and PD-L1 and immune cells 
by using the TIMER database. We analyzed the corre-
lation between TAZ expression and B cells, CD4 + T 
cells, CD8 + T cells, neutrophils, macrophages, and 
dendritic cells. The results showed that there was a 
significant positive relationship between TAZ expres-
sion levels and the infiltration of CD4 + T cells, and 
there were no significant correlations between the 
levels of TAZ and B cells, CD8 + T cells, macrophages, 
neutrophils, and dendritic cells in CESCs (Fig. 4A). We 
also analyzed the relationship between PD-L1 expres-
sion and B cells, CD4 + T cells, CD8 + T cells, neu-
trophils, macrophages, and dendritic cells. The result 
demonstrated that the expression of PD-L1 was associ-
ated with CD4 + T, cells CD8 + T cells, macrophages, 
neutrophils, and dendritic cells in CESCs, but was not 
correlated with B cells (Fig. 4B).
Correlation analysis between TAZ expression and immune 
checkpoints
Based on high expression of TAZ and PD-L1, the signifi-
cant association between CD4 + T cells and the expres-
sion of TAZ and PD-L1 in CC, we also want to know 
whether there is a significant correlation between TAZ 
and PD-L1. We found that TAZ expression was positively 
correlated with PD-L1 and PD-1 expression by utilizing 
Fig. 5 Correlation of TAZ expression with immune checkpoints. A The R2 database showed a positive association between TAZ and PD-L1 in CC. 
B The R2 database showed a positive association between TAZ and PD-1 in CC. C The R2 database showed a non-significant positive association 
between TAZ and PD-L1 in CC
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the R2 database. However, there is no significant corre-
lation between TAZ and CTLA4 expression via R2 data-
base (Fig. 5A–C). Additionally, we also used the GEPIA 
database to investigate the correlation between TAZ 
expression and immune checkpoints (PD-L1, PD-1, and 
CTLA4). We found that TAZ expression was positively 
associated with PD-L1; however, it was negatively corre-
lated with PD-1 and CTLA4 (Fig. 4C).
PD‑L1 is upregulated by TAZ in CC cells
Given the positive correlation between TAZ and PD-L1, 
we want to know whether PD-L1 can be regulated by 
TAZ. We transfected TAZ siRNA into HeLa cells. PD-L1 
was significantly decreased by TAZ siRNA at the mRNA 
level, as shown by qRT–PCR, in contrast with the normal 
and negative control groups (Fig.  6A). When we trans-
fected TAZ plasmid into HeLa cells, the level of PD-L1 
mRNA was upregulated compared with the normal and 
negative control groups (Fig. 6B). Furthermore, when we 
transfected TAZ plasmid and PD-L1 siRNA into CC cells, 
the mRNA level of PD-L1 was downregulated compared 
with that in the TAZ plasmid groups (Fig. 6B). Similarly, 
the protein expression of PD-L1 was inhibited in groups 
of TAZ siRNA and PD-L1 siRNA compared with normal 
control groups (Fig.  7A). In addition, the expression of 
PD-L1 was downregulated in groups of TAZ plasmid and 
PD-L1 siRNA compared with that in the TAZ plasmid 
groups (Fig. 7B).
TAZ improves cell proliferation of CC Cells via upregulating 
PD‑L1
Previous studies have shown that TAZ can make an 
important role on CC, and we also found there is a posi-
tive correlation between TAZ and PD-L1. Therefore, we 
next evaluated whether TAZ can regulate the character-
istics of cancer cells via PD-L1.
To determine the influence of TAZ on CC cells, we used 
a CCK-8 assay to assess cell proliferative capacity. There 
was a decrease in cell proliferation in the TAZ siRNA and 
PD-L1 siRNA groups compared with the control and nega-
tive control groups (Fig. 8A, P < 0.05). The cell groups trans-
fected with the TAZ plasmid showed higher cell growth 
ability than the control and negative groups (Fig.  8B, 
P < 0.05). The cell proliferation capacity in the TAZ plasmid 
and PD-L1 siRNA cell groups was decreased compared 
with that in the TAZ plasmid group (Fig. 8B, P < 0.05).
TAZ improves cell invasion of CC cells via upregulating 
PD‑L1
The invasion ability of the cell groups transfected with TAZ 
siRNA and PD-L1 siRNA was weakened compared with 
that of the control and negative groups (Fig.  8C, P < 0.05) 
according to the Transwell assay. There was an increase in 
cell invasion ability in the TAZ plasmid groups, even if the 
statistical analysis was not significant (Fig. 8D). In addition, 
the groups transfected with the TAZ plasmid and PD-L1 
siRNA showed lower invasion capacity than the groups 
Fig. 6 The expression of PD-L1 mRNA in CC. A The level of PD-L1 mRNA was lower in the TAZ siRNA and PD-L1 siRNA groups than in the control 
groups. B PD-L1 expression was upregulated in the TAZ plasmid groups compared with the control groups, and PD-L1 expression was decreased in 
the TAZ plasmid and PD-L1 siRNA groups compared with the TAZ plasmid groups. *P < 0.05. CC, cervical cancer
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transfected with only the TAZ plasmid (Fig. 8D, P < 0.05). 
Additionally, the protein expression of MMP-2 and MMP-9 
in was decreased in groups of TAZ siRNA and PD-L1 
siRNA compared with that of the control and negative 
groups (Fig. 9A, P < 0.05). the groups transfected with the 
TAZ plasmid and PD-L1 siRNA showed lower expression 
of PD-L1 than the groups transfected with only the TAZ 
plasmid (Fig. 9B, P < 0.05).
TAZ inhibits cell apoptosis of CC cells via upregulating 
PD‑L1
The present study further assessed whether TAZ 
could inhibit apoptosis in CC by regulating PD-L1. An 
annexin V/PI apoptosis assay was performed using flow 
cytometry. The percentages of apoptosis in the groups 
transfected with TAZ siRNA and PD-L1 siRNA were 
16.9% and 26.1%, respectively, which were higher than 
those in the control groups (Fig. 10A, P < 0.05). The per-
cent of apoptosis in the groups transfected with the TAZ 
plasmid was 0.6%, which was lower than that in the con-
trol groups (Fig.  10B, P < 0.05). Additionally, when we 
transfected TAZ plasmid and PD-L1 siRNA into the cell 
groups, the percent of apoptosis was increased compared 
with that in the TAZ plasmid groups (Fig. 10B, P < 0.05).
The study also evaluated the expression of Bcl-2 
and Caspase-3, and the expression of Bcl-2 in groups 
Fig. 7 The protein expression of PD-L1 in CC. A The level of PD-L1 was lower in the TAZ siRNA and PD-L1 siRNA groups than in the control groups. 
B PD-L1 expression was upregulated in the TAZ plasmid groups compared with the control groups, and PD-L1 expression was decreased in the TAZ 
plasmid and PD-L1 siRNA groups compared with the TAZ plasmid groups. *P < 0.05. CC, cervical cancer
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transfected with TAZ plasmid and PD-L1 siRNA was 
decreased compared with that in the TAZ plasmid groups 
(Fig. 10C). In contrast, the expression of Caspase-3 was 
increased in the TAZ plasmid and PD-L1 siRNA groups 
compared with that in the TAZ plasmid group (Fig. 10C).
Discussion
CC is considered a common gynecological cancer in 
women worldwide, with 570,000 reported incident cases 
documented each year [19]. Therefore, it is of utmost 
importance to identify novel treatment strategies for CC.
Here, we have defined TAZ, a Hippo signaling trans-
ducer and a novel oncogene, as being responsible for 
CC tumorigenesis. Our data revealed that TAZ is 
significantly overexpressed in CC and is closely corre-
lated with PD-L1. Notably, TAZ promotes proliferation, 
anti‐apoptosis, migration, and invasion by regulating 
PD-L1 in CC. We indicated a novel mechanism of TAZ 
in CC, which is extremely important for the treatment of 
CC.
Cancer research in the past decade has indicated that 
the Hippo pathway regulates cell proliferation, tissue 
homeostasis, and organ size and is a promoter of tumo-
rigenesis and tumor migration [20, 21]. As a paralog of 
YAP, TAZ shares 46% homology with YAP. In numer-
ous studies, both YAP and TAZ are referred to as a 
pair, as many antibodies detect both proteins due to 
their high similarity. Importantly, YAP and TAZ cannot 
Fig. 8 TAZ and PD-L1 regulates CC progression. A Representative images and quantification of CCK-8 assays indicating the growth and invasion of 
HeLa cells stably transfected with empty vector (mock), TAZ siRNA, and PD-L1 siRNA. B Representative images and quantification of CCK-8 assays 
indicating the growth and invasion of HeLa cells stably transfected with empty vector (mock), TAZ plasmid, and PD-L1 siRNA and TAZ plasmid. C 
and D Representative images of Matrigel invasion assays showing the growth and invasion of HeLa cells stably transfected with TAZ siRNA, PD-L1 
siRNA, TAZ plasmid, and PD-L1 siRNA and TAZ plasmid. *P < 0.05
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compensate for each other [22]. Previous studies found 
that active TAZ increased migration and colony forming 
ability but had no effect on proliferation. This result was 
associated with increased expression of E-cadherin, FN1, 
vimentin, and B-catenin [23]. TAZ can function indepen-
dently of YAP to enhance DNA synthesis and appears 
to be important in cell cycle regulation [24]. A previous 
study analyzed the function of the Hippo pathway in 308 
CC patients from The Cancer Genome Atlas (TCGA) 
and showed that TAZ was continually amplified in CC, 
and the high genetic expression of TAZ was associated 
with poor prognosis [12]. In recent years, several tumors, 
including thyroid carcinoma [25], rectal cancer [26], and 
colon cancer [27], have shown high levels of TAZ, sug-
gesting that it may function as a promoter in tumorigen-
esis. Similarly, we also found that TAZ is overexpressed 
in CC and can induce growth and metastasis and inhibit 
apoptosis of CC cells.
How does TAZ affect tumorigenesis and tumor 
migration? A recent study found that the overexpres-
sion of several genes in the JAK–STAT3 pathway is 
induced by active YAP1 and TAZ interacting with the 
transcription factor TEAD [28]. This pathway controls 
the response to inflammatory cytokines, is present at 
high levels in pancreatic tumors, and can lead to PanIN 
progression in KRasG12D mice [29, 30]. In addition, 
TAZ is necessary for TGF-β response elements and 
maintains the nuclear accumulation of the Smad2/3-
Smad4 complex and stem cell self-renewal mediated by 
TGF-β [31]. Noticeably, YAP and TAZ can have a posi-
tive effect on the expression of the immune checkpoint 
molecule PD-L1, thereby suppressing the antitumor 
ability of T cells in several different models [32]. Feng 
et  al. demonstrated that the pH of the extracellular 
environment can affect the activity of Hippo signaling 
in human lung adenocarcinoma, which induces TAZ to 
upregulate the level of PD-L1 [33]. PD-L1 or B7-H1 is 
Fig. 9 TAZ promotes metastasis of CC cells associated with PD-L1. A and B The expression of MMP-2 and MMP-9 was measured by western blotting 
assay
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the major ligand for PD-1 [34]. PD-L1 is expressed in 
immune cells, including activated T cells, B cells, den-
dritic cells, macrophages, and various tumor cells [35, 
36]. Normally, PD-L1 expression maintains the home-
ostasis of the immune response. PD-L1 expressed by 
cancer cells and infiltrating immune cells can bind to 
PD-1 on T cells and then suppress the functions of T 
cells in the tumor microenvironment [37, 38]. Prog-
nosis determined by oncological histology is closely 
related to the expression of PD-L1; therefore, inter-
vention in PD-L1 expression can be the key to tumor 
therapy [39–42]. Multiple studies identified PD-L1 as 
a direct transcriptional target of YAP/TAZ/TEAD and 
showed that YAP and/or TAZ activation upregulates 
PD-L1 in human breast cancer, NSCLC, mesothe-
lioma and melanoma cells [43]. We characterized the 
molecular mechanisms by which TAZ enhances PD-L1 
Fig. 10 TAZ suppresses apoptosis of CC cells associated with PD-L1. A Apoptosis was induced in TAZ siRNA cell group and PD-L1 siRNA cell groups 
Compared with control cell group. B Apoptosis was inhibited in plasmidTAZ cell group Compared with control cell group. Apoptosis was induced in 
plasmidTAZ and siPD-L1 groups Compared with plasmid TAZ cell group, P < 0.05. C The expression of Bcl-2 and Caspase-3 was measured by western 
blotting assay
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expression by binding to the PD-L1 promoter through 
the TEAD family of transcription factors.
Recent data suggested that PD-L1 is overexpressed 
in CC cells and can promote the growth and metas-
tasis of CC [44]. PD-L1 is an important biomarker for 
evaluating CC prognosis and clinical pathological char-
acteristics [45]. Consistent with this, our results also 
showed that TAZ expression is significantly correlated 
with PD-L1 expression in CC, and TAZ inhibited the 
percent apoptosis of cervical cancer cells by regulating 
PD-L1 and promoted proliferation and metastasis.
Research developments have led to an entirely new 
class of drugs, antibodies directed against PD-L1/PD-1, 
which promote the body’s immune system to fight can-
cer. The expression and roles of TAZ and PD-L1 in the 
progression of CC provide great potential for observing 
new targeted cancer therapies.
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